Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sean E Collins

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
River Research and Applications|June 23, 2025
<i>In-situ</i> measurement of dissolved organic carbon and total organic carbon in fresh surface waters: lab validation of a portable field meterSean E Collins, Margaret E Moulton, Joseph E Flotemersch
Drugs|December 18, 2015
Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected PatientsSean E Collins, Philip M Grant, Robert W Shafer
Ecosphere (Washington, D.C)|July 13, 2019
A patchy continuum? Stream processes show varied responses to patch- and continuum-based analysesSean E Collins, Stephen F Matter, Ishi Buffam, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 19, 2024
Susceptibility Screening of HIV-1 Viruses to Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, in People With HIV-1 Suppressed by Antiretroviral TherapyLisa Selzer, Laurie A VanderVeen, Aiyappa Parvangada, et al.
The Journal of Infectious Diseases|November 8, 2025
Resistance Analysis of Low-Level Virologic Rebound During HIV-1 Treatment with Lenacapavir and Broadly Neutralizing Antibodies Teropavimab and ZinlirvimabLisa Selzer, Sally Demirdjian, Brie Falkard, et al.
Plos One|June 4, 2015
Whole Genome Sequencing Investigation of a Tuberculosis Outbreak in Port-au-Prince, Haiti Caused by a Strain with a "Low-Level" rpoB Mutation L511P - Insights into a Mechanism of Resistance EscalationOksana Ocheretina, Lishuang Shen, Vincent E Escuyer, et al.
Journal of the International AIDS Society|July 1, 2014
Gender inequality and HIV transmission: a global analysisEugene T Richardson, Sean E Collins, Tiffany Kung, et al.
AIDS (London, England)|May 26, 2018
Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamidePaul E Sax, Edwin DeJesus, Gordon Crofoot, et al.
The Journal of Antimicrobial Chemotherapy|April 21, 2021
Three-year study of pre-existing drug resistance substitutions and efficacy of bictegravir/emtricitabine/tenofovir alafenamide in HIV-1 treatment-naive participantsRima K Acosta, Grace Q Chen, Silvia Chang, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 16, 2021
Evaluation of Broadly Neutralizing Antibody Sensitivity by Genotyping and Phenotyping for Qualifying Participants to HIV Clinical TrialsBrian Moldt, Aiyappa Parvangada, Ross Martin, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
River Research and Applications|June 23, 2025
<i>In-situ</i> measurement of dissolved organic carbon and total organic carbon in fresh surface waters: lab validation of a portable field meterSean E Collins, Margaret E Moulton, Joseph E Flotemersch
Drugs|December 18, 2015
Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected PatientsSean E Collins, Philip M Grant, Robert W Shafer
Ecosphere (Washington, D.C)|July 13, 2019
A patchy continuum? Stream processes show varied responses to patch- and continuum-based analysesSean E Collins, Stephen F Matter, Ishi Buffam, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 19, 2024
Susceptibility Screening of HIV-1 Viruses to Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, in People With HIV-1 Suppressed by Antiretroviral TherapyLisa Selzer, Laurie A VanderVeen, Aiyappa Parvangada, et al.
The Journal of Infectious Diseases|November 8, 2025
Resistance Analysis of Low-Level Virologic Rebound During HIV-1 Treatment with Lenacapavir and Broadly Neutralizing Antibodies Teropavimab and ZinlirvimabLisa Selzer, Sally Demirdjian, Brie Falkard, et al.
Plos One|June 4, 2015
Whole Genome Sequencing Investigation of a Tuberculosis Outbreak in Port-au-Prince, Haiti Caused by a Strain with a "Low-Level" rpoB Mutation L511P - Insights into a Mechanism of Resistance EscalationOksana Ocheretina, Lishuang Shen, Vincent E Escuyer, et al.
Journal of the International AIDS Society|July 1, 2014
Gender inequality and HIV transmission: a global analysisEugene T Richardson, Sean E Collins, Tiffany Kung, et al.
AIDS (London, England)|May 26, 2018
Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamidePaul E Sax, Edwin DeJesus, Gordon Crofoot, et al.
The Journal of Antimicrobial Chemotherapy|April 21, 2021
Three-year study of pre-existing drug resistance substitutions and efficacy of bictegravir/emtricitabine/tenofovir alafenamide in HIV-1 treatment-naive participantsRima K Acosta, Grace Q Chen, Silvia Chang, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 16, 2021
Evaluation of Broadly Neutralizing Antibody Sensitivity by Genotyping and Phenotyping for Qualifying Participants to HIV Clinical TrialsBrian Moldt, Aiyappa Parvangada, Ross Martin, et al.
Pageof 3